Chapter 84 Chapter 84 Strontium Ranelate in the Prevention of Osteoporotic Fractures Copyright © 2013 Elsevier Inc. All rights reserved.

Slides:



Advertisements
Similar presentations
Chapter 68 Chapter 68 Fracture Risk Assessment: The Development and Application of FRAX ® Copyright © 2013 Elsevier Inc. All rights reserved.
Advertisements

Chapter 39 Animal Models for Osteoporosis
Chapter 80 Chapter 80 Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P
Denosumab NICE technology appraisal guidance 204 October 2010.
Copyright © 2013 Elsevier Inc. All rights reserved.
Glucocorticoid-Induced Osteoporosis (GIO) Nguyen Thy Khue, MD, PhD Department of Endocrinology, HoChiMinh City University of Medicine and Pharmacy.
Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
1 Chapter 24 - Renal Cortical and Medullary Microcirculations: Structure and Function Copyright © 2013 Elsevier Inc. All rights reserved.
1 Chapter 33 - Sodium and Chloride Transport: Proximal Nephron Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 50: Strontium Ranelate in the Prevention of Osteoporotic Fractures René Rizzoli.
Modeling Constraints with Parametrics
Copyright © 2016 Elsevier Inc. All rights reserved.
Chapter 41 Work-Related Musculo-Skeletal Disorders
Vert Non-Vert Hip ** ** Zoledronic Acid3 Zoledronic Acid4 Denosumab5
Chapter 65 - The Hormonal Regulation of Calcium Metabolism
Bisphosphonate exposure and Atypical Femoral Fractures
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 11.
Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis  Miyuki Takasu, Yoko Kaichi, Kazuo.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis 
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 10.
Chapter 28 - Renal Hyperplasia and Hypertrophy
Copyright © 2012, Elsevier Inc. All rights Reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Modeling Cross-Cutting Relationships with Allocations
Portable Biotechnology
© 2012 Elsevier, Inc. All rights reserved.
Modeling Text-Based Requirements and their Relationship to Design
Modeling Functionality with Use Cases
Customizing SysML for Specific Domains
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 91 Epidemiology of Headache in Women:
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 12.
Chapter 6.
Copyright © 2012, Elsevier Inc. All rights Reserved.
© 2012 Elsevier, Inc. All rights reserved.
Chapter 103 Long-Term Care: The Global Impact
Chapter 01.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 08.
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 64 - Renal Calcium Metabolism
Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 57 - Renal Ammonium Ion Production and Excretion
© 2015 Elsevier, Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright © 2012, Elsevier Inc. All rights Reserved.
Chapter 15 Contraception
Chapter 78 Vaccination and Screening in Cervical Cancer
Copyright © 2013 Elsevier Inc. All rights reserved.
Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.
Chapter 15.
Chapter 77 Cervical Cancer: Burden of Disease
Chapter 20 Assisted Reproductive Technologies
Chapter 3.
© 2015 Elsevier, Inc. All rights reserved.
Presentation transcript:

Chapter 84 Chapter 84 Strontium Ranelate in the Prevention of Osteoporotic Fractures Copyright © 2013 Elsevier Inc. All rights reserved.

FIGURE 84.1 Plot showing 1-, 3-, and 5-year vertebral and nonvertebral fracture risk results from SOTI and TROPOS comparing strontium ranelate and placebo. * Post hoc analysis in a subgroup of women at high risk of fractures (age ≥ 74 years with a T-score ≤ –2.4). PEP, primary end point; SEP, secondary end point; SOTI, Spinal Osteoporosis Therapeutic Intervention; TROPOS, TReatment Of Peripheral Osteoporosis. Source: modified from Marie et al. (2011) [1]. 2

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 84.2 Long-term incidence of fracture with strontium ranelate: 10-year results. Cumulative incidence of new vertebral fracture (A), new nonvertebral fracture (B), and new osteoporotic fracture (C) in the 10-year population between 0 and 5 years of treatment with strontium ranelate and between 6 and 10 years of treatment with strontium ranelate (gray bars) and in the FRAX ® -matched placebo group of TROPOS between 0 and 5 years (white bars). NS, nonsignificant; TROPOS, TReatment Of Peripheral Osteoporosis. Source: modified from Reginster etal. (2012) [16]. 3

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 84.3 Finite element analysis results comparing strontium ranelate and alendronate in a Segmented failure load and trabecular and cortical stress model (relative change from baseline ± standard deviation (SD)). p values between groups are for multiple comparisons (Bonferroni criterion); *p < 0.05; **p < 0.01; *** p < versus baseline. Source: Rizzoli etal. (2011) [30]. 4

Copyright © 2013 Elsevier Inc. All rights reserved. FIGURE 84.4 Effect of strontium ranelate on bone strength following proximal tibia implant insertion in rats. The X-ray image (A) depicts an implant in rat proximal tibia, while the bar chart (B) shows the effects of strontium ranelate (625mg/kg 5/7 days) and control on pull-out strength (N) of a titanium implant inserted in proximal tibia. Values are mean ± standard error of the mean (SEM). *p < 0.05 compared to control. Source: modified from Maimoun etal. (2010) [67]. 5